US EditionPublished • loading... • Updated
AstraZeneca India Gets CDSCO Nod to Introduce Durvalumab for Advanced Liver Cancer - The Canadian Media
Summary by thecanadianmedia.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
AstraZeneca Pharma India receives CDSCO approval for Durvalumab for patients with uHCC
AstraZeneca Pharma India, a global, science-led biopharmaceutical company, announced that Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Durvalumab solution for infusion (120 mg/2.4 mL and 500 mg/10 mL), for the treatment of patients with unresectable hepatocellular carcinoma (uHCC),who have not received prior systemic therapy. In India, according to GLOBOCAN 2022, more than 38,000 new cases of HCC …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
